NCT04524195 is a Phase 1 clinical trial of [18F]F-AraG Injection in Non-small Cell Lung Cancer (NSCLC), sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Who is sponsoring NCT04524195?

NCT04524195 is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

What drugs are being tested in NCT04524195?

Interventions in NCT04524195: [18F]F-AraG Injection.

What condition does NCT04524195 study?

NCT04524195 studies Non-small Cell Lung Cancer (NSCLC).

Is NCT04524195 still recruiting?

NCT04524195 is currently terminated. Last updated 17 January 2024.

Last reviewed 2024-01-17 · How we verify

NCT04524195

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)

Terminated Phase 1 Last updated 17 January 2024

What this trial tests

Phase 1 trial testing [18F]F-AraG Injection in Non-small Cell Lung Cancer (NSCLC) in 4 participants. Terminated before completion.

Timeline

1 February 2021

Primary endpoint
27 November 2023

27 November 2023

Quick facts

Lead sponsor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	4
Start date	1 February 2021
Primary completion	27 November 2023
Estimated completion	27 November 2023
Sites	1 location across United States

Drugs / interventions tested

[18F]F-AraG Injection — full drug profile →

Conditions studied

Non-small Cell Lung Cancer (NSCLC) — all drugs for Non-small Cell Lung Cancer (NSCLC) →

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — full company profile →

Who can join

18 and older, any sex, with Non-small Cell Lung Cancer (NSCLC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, single center, single-arm clinical trial in 20 patients with non-small cell lung cancer (NSCLC) undergoing PD-1/PD-L1-directed therapy. This research is being done to find out if the radioactive compound called \[18F\]F-AraG is a helpful imaging agent for detecting changes in cancer's anti-tumor immune response (or activation of T-cell) levels for non-small cell lung cancer (NSCLC) patients who will receive a cancer immunotherapy regimen (immunotherapy works by encouraging the body's own immune system to attack the cancer cells).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Molecular Immune Targeted Imaging of Tumor Microenvironment.
Rakhshandehroo T, Smith BR, Glockner HJ, Rashidian M, et al · · 2022 · cited 19× · PMID 35223381 · DOI 10.7150/ntno.66556
Clinical Application of ImmunoPET Targeting Checkpoint Inhibitors.
Abenavoli EM, Linguanti F, Calabretta R, Delgado Bolton RC, et al · · 2023 · cited 11× · PMID 38067379 · DOI 10.3390/cancers15235675
Advancing In Vivo Detection of T-Cell Function: Development and Preclinical Evaluation of <sup>89</sup>Zr-Ivuxolimab, a Human OX40 PET Tracer.
Kalita M, Kuo RC, Reyes ST, Colburg DRC, et al · · 2025 · cited 1× · PMID 40707142 · DOI 10.2967/jnumed.125.269799
Metabolic [¹⁸F]F-AraG PET imaging of T Cell activation: a functional complement to cell-specific immune tracers.
Almutairi WM, Gopaulchan M, Bhaskara R, Zheng QH, et al · · 2026 · PMID 42001384 · DOI 10.1186/s13550-026-01436-6

Verify or expand the search:

Other recruiting trials for Non-small Cell Lung Cancer (NSCLC)

Currently open trials in the same condition.

NCT07361497 — A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresec · Phase 3 · recruiting
NCT07288177 — Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer · Phase 2 · recruiting
NCT07223047 — A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agent · Phase 1, PHASE2 · recruiting
NCT07291037 — Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic N · Phase 3 · recruiting
NCT07140016 — A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) · Phase 1 · recruiting

Other Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins trials

Trials by the same sponsor.

NCT07424222 — Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) · Phase 1 · not yet recruiting
NCT06210854 — Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+ · Phase 2 · not yet recruiting
NCT07360119 — Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors · NA · not yet recruiting
NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04524195 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Last refreshed: 17 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04524195.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing